Ara
Toplam kayıt 6, listelenen: 1-6
PET-MRI Findings of Two Patients with Breast Carcinoma before Treatment
(AVES, 2016)
Integrated positron-emission tomography-magnetic resonance imaging (PET-MRI) is a new hybrid simultaneous imaging modality with higher soft tissue contrast and lower radiation doses compared with PET-CT. Two patients who ...
Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients
(IMPRIMATUR PUBLICATIONS, 2016)
Purpose: The receptor status of breast cancer plays a critical role in clinical practice. During the metastatic process, a change in the biological characteristics of the tumor can be seen. This study aimed to investigate ...
A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma
(LIPPINCOTT WILLIAMS & WILKINS, 2016)
Sunitinib has become a standard treatment agent for metastatic renal cell carcinoma (RCC) for several years. However, various adverse events have been reported. We present a rare adverse effect of hyperammonemic encephalopathy ...
Dramatic Response to Catumaxomab Treatment for Malign Ascites Related to Renal Cell Carcinoma With Sarcomotoid Differentiation
(LIPPINCOTT WILLIAMS & WILKINS, 2016)
Refractory malignant ascites (MA) is a common complication in cancer patients. Renal cell carcinoma (RCC) is rarely present with peritoneal ascites, which is commonly associated with carcinomas of the gastrointestinal and ...
Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
(TERMEDIA PUBLISHING HOUSE LTD, 2016)
Aim of the study: Sunitinib-related side effects may develop as a result of the pharmacokinetic pathway affects the of the drug. Material and methods: Data on mRCC patients were obtained from the hospital archives. Outcomes ...
Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study
(SPRINGER, 2016)
The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of ...